Aberrant genes promoter methylation in neural crest-derived tumors

Annamaria La Torre, Lucia Anna Muscarella, Paola Parrella, Teresa Balsamo, Michele Bisceglia, Vanna Maria Valori, Antonella La Torre, Raffaela Barbano, Eleonora Perrella, Maria Luana Poeta, Gennaro Melchionda, Giuseppe Merla, Evaristo Maiello, Riccardo Pellicano, Vito Michele Fazio

Research output: Contribution to journalArticle

Abstract

Disturbances in the epigenetic landscape by aberrant methylation of CpG islands can lead to inactivation of cancer-related genes in solid tumors. We analyzed the promoter methylation status of 6 genes previously reported as cancer-specific methylated (MCAM, SSBP2, NISCH, B4GALT1, KIF1A and RASSF1A) in 38 neural crest-derived tumors by quantitative methylation- specific real-time PCR (QMSP). The results demonstrated that the determination of the methylation status of RASSF1A is able to distinguish between normal and tumor samples in cutaneous melanomas, lung carcinoids and small bowel carcinoids. MCAM methylation levels were significantly higher in lung carcinoids tumors (p=0.001), suggesting that this alteration may represent a molecular biomarker in this tumor type.

Original languageEnglish
JournalInternational Journal of Biological Markers
Volume27
Issue number4
DOIs
Publication statusPublished - Oct 2012

    Fingerprint

Keywords

  • Mcam
  • Methylation
  • Neural crest-derived tumors
  • Rassf1a

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this